The use of selegiline in Alzheimer's patients with behavior problems

D. L. Goad, C. M. Davis, P. Liem, C. C. Fuselier, J. R. McCormack, Keith Melvin Olsen

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background: Currently there is no regimen for managing the inappropriate behavior seen in Alzheimer's disease that does not cause significant patient sedation. Preliminary evidence suggests selegiline may be effective in behavioral modification without the adverse effects observed with other regimens. The purpose of this study was to document the efficacy of selegiline in Alzheimer's patients with behavior problems. Method: Eight Alzheimer's patients (6 women and 2 men) ranging in age from 50 to 82 years (mean ± SD = 74.0 ± 10.5) were enrolled in this single-blind study. Patients received selegiline 10 mg each day for 8 weeks. Prior to drug administration and at the end of Weeks 1, 2, 4, 6, and 8, patients were evaluated for behavior (BEHAVE-AD), cognitive function (Mini-Mental State Examination), and caregiver stress (Caregiver Burden Scale). Results: Of eight enrolled patients, five were available for analysis. No statistically significant differences were found between mean baseline and mean 8-week scores for any of the three tests. However, clinical significance was noted by improvement in cognition (orientation and recall), caregiver stress, and behavior. Behavior was noted to improve in the areas of paranoid and delusional ideation, hallucinations, activity disturbances, anxiety, and phobias. Conclusion: These data suggest that some Alzheimer's patients with behavior problems may benefit from selegiline therapy.

Original languageEnglish (US)
Pages (from-to)342-345
Number of pages4
JournalJournal of Clinical Psychiatry
Volume52
Issue number8
StatePublished - Jan 1 1991

Fingerprint

Selegiline
Caregivers
Cognition
Single-Blind Method
Phobic Disorders
Hallucinations
Problem Behavior
Alzheimer Disease
Anxiety
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Goad, D. L., Davis, C. M., Liem, P., Fuselier, C. C., McCormack, J. R., & Olsen, K. M. (1991). The use of selegiline in Alzheimer's patients with behavior problems. Journal of Clinical Psychiatry, 52(8), 342-345.

The use of selegiline in Alzheimer's patients with behavior problems. / Goad, D. L.; Davis, C. M.; Liem, P.; Fuselier, C. C.; McCormack, J. R.; Olsen, Keith Melvin.

In: Journal of Clinical Psychiatry, Vol. 52, No. 8, 01.01.1991, p. 342-345.

Research output: Contribution to journalArticle

Goad, DL, Davis, CM, Liem, P, Fuselier, CC, McCormack, JR & Olsen, KM 1991, 'The use of selegiline in Alzheimer's patients with behavior problems', Journal of Clinical Psychiatry, vol. 52, no. 8, pp. 342-345.
Goad DL, Davis CM, Liem P, Fuselier CC, McCormack JR, Olsen KM. The use of selegiline in Alzheimer's patients with behavior problems. Journal of Clinical Psychiatry. 1991 Jan 1;52(8):342-345.
Goad, D. L. ; Davis, C. M. ; Liem, P. ; Fuselier, C. C. ; McCormack, J. R. ; Olsen, Keith Melvin. / The use of selegiline in Alzheimer's patients with behavior problems. In: Journal of Clinical Psychiatry. 1991 ; Vol. 52, No. 8. pp. 342-345.
@article{f03c30b11e1c4d7e9128ecbed3443f86,
title = "The use of selegiline in Alzheimer's patients with behavior problems",
abstract = "Background: Currently there is no regimen for managing the inappropriate behavior seen in Alzheimer's disease that does not cause significant patient sedation. Preliminary evidence suggests selegiline may be effective in behavioral modification without the adverse effects observed with other regimens. The purpose of this study was to document the efficacy of selegiline in Alzheimer's patients with behavior problems. Method: Eight Alzheimer's patients (6 women and 2 men) ranging in age from 50 to 82 years (mean ± SD = 74.0 ± 10.5) were enrolled in this single-blind study. Patients received selegiline 10 mg each day for 8 weeks. Prior to drug administration and at the end of Weeks 1, 2, 4, 6, and 8, patients were evaluated for behavior (BEHAVE-AD), cognitive function (Mini-Mental State Examination), and caregiver stress (Caregiver Burden Scale). Results: Of eight enrolled patients, five were available for analysis. No statistically significant differences were found between mean baseline and mean 8-week scores for any of the three tests. However, clinical significance was noted by improvement in cognition (orientation and recall), caregiver stress, and behavior. Behavior was noted to improve in the areas of paranoid and delusional ideation, hallucinations, activity disturbances, anxiety, and phobias. Conclusion: These data suggest that some Alzheimer's patients with behavior problems may benefit from selegiline therapy.",
author = "Goad, {D. L.} and Davis, {C. M.} and P. Liem and Fuselier, {C. C.} and McCormack, {J. R.} and Olsen, {Keith Melvin}",
year = "1991",
month = "1",
day = "1",
language = "English (US)",
volume = "52",
pages = "342--345",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "8",

}

TY - JOUR

T1 - The use of selegiline in Alzheimer's patients with behavior problems

AU - Goad, D. L.

AU - Davis, C. M.

AU - Liem, P.

AU - Fuselier, C. C.

AU - McCormack, J. R.

AU - Olsen, Keith Melvin

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Background: Currently there is no regimen for managing the inappropriate behavior seen in Alzheimer's disease that does not cause significant patient sedation. Preliminary evidence suggests selegiline may be effective in behavioral modification without the adverse effects observed with other regimens. The purpose of this study was to document the efficacy of selegiline in Alzheimer's patients with behavior problems. Method: Eight Alzheimer's patients (6 women and 2 men) ranging in age from 50 to 82 years (mean ± SD = 74.0 ± 10.5) were enrolled in this single-blind study. Patients received selegiline 10 mg each day for 8 weeks. Prior to drug administration and at the end of Weeks 1, 2, 4, 6, and 8, patients were evaluated for behavior (BEHAVE-AD), cognitive function (Mini-Mental State Examination), and caregiver stress (Caregiver Burden Scale). Results: Of eight enrolled patients, five were available for analysis. No statistically significant differences were found between mean baseline and mean 8-week scores for any of the three tests. However, clinical significance was noted by improvement in cognition (orientation and recall), caregiver stress, and behavior. Behavior was noted to improve in the areas of paranoid and delusional ideation, hallucinations, activity disturbances, anxiety, and phobias. Conclusion: These data suggest that some Alzheimer's patients with behavior problems may benefit from selegiline therapy.

AB - Background: Currently there is no regimen for managing the inappropriate behavior seen in Alzheimer's disease that does not cause significant patient sedation. Preliminary evidence suggests selegiline may be effective in behavioral modification without the adverse effects observed with other regimens. The purpose of this study was to document the efficacy of selegiline in Alzheimer's patients with behavior problems. Method: Eight Alzheimer's patients (6 women and 2 men) ranging in age from 50 to 82 years (mean ± SD = 74.0 ± 10.5) were enrolled in this single-blind study. Patients received selegiline 10 mg each day for 8 weeks. Prior to drug administration and at the end of Weeks 1, 2, 4, 6, and 8, patients were evaluated for behavior (BEHAVE-AD), cognitive function (Mini-Mental State Examination), and caregiver stress (Caregiver Burden Scale). Results: Of eight enrolled patients, five were available for analysis. No statistically significant differences were found between mean baseline and mean 8-week scores for any of the three tests. However, clinical significance was noted by improvement in cognition (orientation and recall), caregiver stress, and behavior. Behavior was noted to improve in the areas of paranoid and delusional ideation, hallucinations, activity disturbances, anxiety, and phobias. Conclusion: These data suggest that some Alzheimer's patients with behavior problems may benefit from selegiline therapy.

UR - http://www.scopus.com/inward/record.url?scp=0025940744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025940744&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 342

EP - 345

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 8

ER -